These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 17889845)

  • 21. [The reflection of the dynamics of the serum markers CA l5.3 and CEA in breast cancer].
    Cianga C; Suliman I
    Rev Med Chir Soc Med Nat Iasi; 1998; 102(3-4):93-5. PubMed ID: 10756852
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serum tumor markers in skeletal metastasis.
    Tsukushi S; Katagiri H; Kataoka T; Nishida Y; Ishiguro N
    Jpn J Clin Oncol; 2006 Jul; 36(7):439-44. PubMed ID: 16815865
    [TBL] [Abstract][Full Text] [Related]  

  • 23. An immunoassay for measuring fragments of newly synthesized collagen type I produced during metastatic invasion of bone.
    Cloos PA; Lyubimova N; Solberg H; Qvist P; Christiansen C; Byrjalsen I; Christgau S
    Clin Lab; 2004; 50(5-6):279-89. PubMed ID: 15209436
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor markers in breast cancer monitoring should be scheduled according to initial stage and follow-up time: a prospective study on 859 patients.
    Gion M; Peloso L; Mione R; Vignati G; Fortunato A; Saracchini S; Biasioli R; Gulisano M; Cappelli G
    Cancer J; 2001; 7(3):181-90. PubMed ID: 11419026
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Diagnostic value of bone remodeling markers in the diagnosis of bone metastases in patients with breast cancer.
    Pectasides D; Farmakis D; Nikolaou M; Kanakis I; Kostopoulou V; Papaconstantinou I; Karamanos NK; Economopoulos T; Raptis SA
    J Pharm Biomed Anal; 2005 Feb; 37(1):171-6. PubMed ID: 15664758
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N(1),N(12)-Diacetylspermine as a sensitive and specific novel marker for early- and late-stage colorectal and breast cancers.
    Hiramatsu K; Takahashi K; Yamaguchi T; Matsumoto H; Miyamoto H; Tanaka S; Tanaka C; Tamamori Y; Imajo M; Kawaguchi M; Toi M; Mori T; Kawakita M
    Clin Cancer Res; 2005 Apr; 11(8):2986-90. PubMed ID: 15837752
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evaluation of the IMMULITE BR-MA and CEA assays and comparison with immunoradiometric assays for CA15-3 and CEA in breast cancer.
    Murray A; Willsher P; Price MR; Dixon AR; Robertson JF
    Anticancer Res; 1997; 17(3C):1945-9. PubMed ID: 9216649
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A comparative study of four serological tumor markers for the detection of breast cancer.
    Clinton SR; Beason KL; Bryant S; Johnson JT; Jackson M; Wilson C; Holifield K; Vincent C; Hall M
    Biomed Sci Instrum; 2003; 39():408-14. PubMed ID: 12724928
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Evaluation of cancer-induced bone diseases by bone metabolic marker].
    Takahashi S
    Clin Calcium; 2006 Apr; 16(4):581- 90. PubMed ID: 16582508
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of bone markers in a 6-week study to assess the efficacy of oral clodronate in patients with metastatic bone disease.
    Brown JE; McCloskey EV; Dewar JA; Body JJ; Cameron DA; Harnett AN; Ruutu M; Purohit OP; Tähtelä R; Coleman RE
    Calcif Tissue Int; 2007 Nov; 81(5):341-51. PubMed ID: 17874331
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CA15-3: a reliable indicator of metastatic bone disease in breast cancer patients.
    O'Brien DP; Horgan PG; Gough DB; Skehill R; Grimes H; Given HF
    Ann R Coll Surg Engl; 1992 Jan; 74(1):9-11; discussion 12. PubMed ID: 1736805
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Prevalence of elevated serum CA 15-3 at time of metastatic relapse of breast cancer and correlation with hormone receptor status].
    Bensouda Y; André F; Boulet T; Al-Ghuzlan A; Conforti R; Troalen F; Bourgier C; Errihani H; Spielmann M; Delaloge S
    Bull Cancer; 2009 Oct; 96(10):923-8. PubMed ID: 19696005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Usefulness of CEA, CA 15-3 and CA 125 tumor markers in the differential diagnostics of peritoneal effusion].
    Kiluk MS; Rółkowski R; Zawadzki RJ; Wojtukiewicz MZ
    Pol Merkur Lekarski; 2002 Oct; 13(76):298-301. PubMed ID: 12557435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Clinical study of serum tissue polypeptide-specific antigen in breast cancer].
    Zheng H; He BF; Luo RC; You CX; Mai GF; Lu HF
    Di Yi Jun Yi Da Xue Xue Bao; 2003 Aug; 23(8):823-5. PubMed ID: 12919909
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Usefulness of pyridinium crosslinks and CA 15-3 as markers in metastatic bone breast carcinoma.
    Massidda B; Ionta MT; Foddi MR; Mascia L; Bruder F; Aloi MB; Meleddu C; Giannoni MN
    Anticancer Res; 1996; 16(4B):2221-3. PubMed ID: 8694547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bone resorption activity of osteolytic metastatic lung and breast cancers.
    Shih LY; Shih HN; Chen TH
    J Orthop Res; 2004 Nov; 22(6):1161-7. PubMed ID: 15475192
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival.
    Benoy IH; Salgado R; Van Dam P; Geboers K; Van Marck E; Scharpé S; Vermeulen PB; Dirix LY
    Clin Cancer Res; 2004 Nov; 10(21):7157-62. PubMed ID: 15534087
    [TBL] [Abstract][Full Text] [Related]  

  • 38. MMP-2, MMP-9 and activin A blood levels in patients with breast cancer or prostate cancer metastatic to the bone.
    Incorvaia L; Badalamenti G; Rini G; Arcara C; Fricano S; Sferrazza C; Di Trapani D; Gebbia N; Leto G
    Anticancer Res; 2007; 27(3B):1519-25. PubMed ID: 17595770
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The course of the urinary DPD-crosslink secretion in metastatic breast cancer--a possibility for response assessment.
    Lüftner D; Günther S; Flath B; Müller C; Echteroff K; Mergenthaler HG; Wernecke KD; Possinger K
    Anticancer Res; 1999; 19(4A):2537-44. PubMed ID: 10470191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
    Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
    Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.